

## RESULTS OF ANNUAL GENERAL MEETING

**Perth, Australia, 28 November 2017:** Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1 LSL** or the **Company**) advises that the resolutions put to the Annual General Meeting of members today were carried.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, the following statistics are provided in respect of each resolution.

Resolution	For	Against	Abstain	Discretionary
1 Adoption of Remuneration Report	21,783,173	390,060	385,000	2,487,361
2 Re-Election of Peter Gunzburg	22,215,233	59,000	28,966,004	2,486,361
3 Approval to issue Advisor Options to Dr Samuel Janes	49,868,977	1,005,260	365,000	2,487,361
4 Approval of 10% Placement Capacity	50,684,237	190,000	365,000	2,487,361
5 Ratification of Placement Under Listing Rule 7.1	50,146,737	727,500	365,000	2,487,361
6 Ratification of Placement under Listing Rule 7.1A Capacity	50,146,737	727,500	365,000	2,487,361
7 Ratification of Share Issue under Listing Rule 7.1 Capacity to S3 Consortium Pty Ltd <Trading as Stocks Digital)	49,643,677	1,210,560	385,000	2,487,361

All resolutions were carried on a show of hands.



**Pauline Collinson**  
Company Secretary

### ABOUT BARD1 LIFE SCIENCES LTD (BARD1 LSL)

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. Its lead product, the BARD1 Lung Cancer Test, is a blood test in development for early detection of lung cancer, utilising novel tumour markers and a proprietary algorithm. The company's pipeline also includes the BARD1 Ovarian Cancer Test in development for early detection of ovarian cancer, and high-value diagnostic and therapeutic projects at research-stage for multiple cancers. BARD1 LSL is committed to transforming the early detection and prevention of cancer to help improve patients' lives.